Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-08-23
Adverse events
Mild ACTINIC KERATOSIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-02-12 (study day 174.0); relationship: NONE
Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-25 (study day 3.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-25 (study day 3.0); relationship: PROBABLE
Moderate CALCULUS URETHRAL — outcome: RECOVERED/RESOLVED; onset 2013-12-17 (study day 117.0); relationship: NONE
Moderate DEPRESSED MOOD — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-29 (study day -25.0); relationship: NONE
Moderate DYSPEPSIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-02; relationship: NONE
Mild EPISTAXIS — outcome: RECOVERED/RESOLVED; onset 2014-01-03 (study day 134.0); relationship: NONE
Moderate FLANK PAIN — outcome: RECOVERED/RESOLVED; onset 2013-12-15 (study day 115.0); relationship: NONE
Moderate LOWER RESPIRATORY TRACT INFECTION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-10-12 (study day 51.0); relationship: NONE
Moderate LOWER RESPIRATORY TRACT INFECTION — outcome: RECOVERED/RESOLVED; onset 2013-10-12 (study day 51.0); relationship: NONE
Data queries
No data queries.